Skip to main content
SpringerLink
Log in

Adalimumab/infliximab/ustekinumab

Miliary tuberculosis and latent tuberculosis: 4 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. For patient 2, a discrepancy was noted between data given in the text and in the table. In the text, the author has stated that the patient received ustekinumab for 4 years. However, in the table 2 of the article, the duration of ustekinumab therapy has been stated as 32 months. For this case report, we have considered the information provided in the table.

Reference

  • Kaneko S, et al. Mycobacterium tuberculosis infection in psoriatic patients treated with biologics: Real-world data from 18 Japanese facilities. Journal of Dermatology 47: 128-132, No. 2, Feb 2020. Available from: URL: http://doi.org/10.1111/1346-8138.15156

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adalimumab/infliximab/ustekinumab. Reactions Weekly 1797, 18 (2020). https://doi.org/10.1007/s40278-020-76525-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-76525-8

Search

Navigation